Abstracts tagged "population studies"

Abstract Number: 2673 • ACR Convergence 2024
Changes in Mortality Risk After Stopping Glucocorticosteroids – a Population-based Study in Rheumatoid Arthritis
Diane Lacaille¹, Coraline Danieli², Kasra Moolooghy¹ and Michal Abrahamowicz³, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Research Institute of McGill University Health Center (RI-MUHC), Montreal, QC, Canada, ³McGill University, Verdun, Canada
Background/Purpose: Glucocorticosteroid (GC) use is associated with increased mortality risk, especially from cardiovascular diseases (CVD) and infections, with dose and duration of use influencing risk.…
Abstract Number: 0735 • ACR Convergence 2024
ANCA-associated Vasculitis (AAV) and Long-term Risk of Cardiovascular Disease: Large-scale Propensity-matched Global Retrospective Cohort Study
Sebastian Klapa¹, Henry Nording², Marlene Ludwig³, Sabrina Arnold⁴, Khalaf Kridin⁵, Anja Staehle⁶, Ralf Ludwig⁷ and Peter Lamprecht⁴, ¹University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, ²University of Lübeck, Cardioimmunology Research Group, Lübeck, Germany, ³Independent Researcher, Groß Grönau, Germany, ⁴University of Lübeck, Department of Rheumatology and Clinical Immunology, Lübeck, Germany, ⁵5. Bar-Ilan University, Azrieli Faculty of Medicine, Safed, Israel, ⁶University of Lübeck, Department of Rheumatology and Immunology, Lübeck, Germany, ⁷University of Lübeck, Lübeck Institute of Experimental Dermatology, Lübeck, Germany
Background/Purpose: In spite of significantly improved therapy during the last years, long-term morbidity and mortality has remained high in ANCA-associated vasculitis (AAV). The main causes…
Abstract Number: 0997 • ACR Convergence 2024
Geographic and Lifestyle Exposures in Systemic Lupus Erythematosus
Zoe Reed¹, Janis Campbell², Xana Howard¹, Teresa Aberle¹, Bridget Parrish¹, Wade DeJager³, Cristina Arriens¹, Joan Merrill⁴ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²University of Oklahoma Health Sciences Center, Oklahoma City, OK, ³Oklahoma Medical Research Foundation, Oklahoma City, ⁴Oklahoma Medical Research Foundation, Oklahoma City 73104, OK
Background/Purpose: Systemic lupus erythematosus (SLE) has a complex etiology with genetic predispositions interacting with environmental factors. Extensive environmental exposure information is now publicly available based…
Abstract Number: 1223 • ACR Convergence 2024
Community Based Study of Prevalence and Social Factors for Chronic Pain and Fibromyalgia in Women from Western India
Vidit Gupta¹, Diksha Mishra¹, Shikhar Singh¹, Vaishnavi Chowhan¹, Shraddha Thorat¹, Kavita Krishna² and Sandeep Kansurkar³, ¹Bharati Vidyapeeth (Deemed to be University) Medical College, Pune), Pune, Maharashtra, India, ²Bharati Vidyapeeth University Medical College and Hospital, Pune, Maharashtra, India, ³Bharati Vidyapeeth University Medical College, Pune, India
Background/Purpose: Fibromyalgia is a disorder of chronic widespread pain. There is huge burden of this entity in community but there is scarcity of quality studies…
Abstract Number: 1299 • ACR Convergence 2024
Board-Style Rheumatology Teaching for Medicine Residents: Novel Approach to Curriculum Development
Merve Aksoy*, Shadi Jafari-Esfahani*, Yasaman Ahmadzadeh and Katarzyna Gilek-Seibert, Roger Williams Medical Center, Providence, RI
Background/Purpose: During their training, internal medicine (IM) residents often have limited exposure to rheumatology, resulting in decreased confidence levels and inadequate scores on the In-training…
Abstract Number: 1485 • ACR Convergence 2024
Genetic Contributions to Systemic Lupus Erythematosus: Concordance Rates in California Twins
Rashmi Dhital¹, Jia Yin Wan², Kenneth Kalunian³ and Wendy Cozen⁴, ¹UC San Diego, Brentwood, TN, ²Samueli School of Public Health, University of California Irvine, Irvine, CA, ³University of California San Diego, La Jolla, CA, ⁴University of California Irvine, Irvine
Background/Purpose: Systemic lupus erythematosus (SLE) is influenced by both genetic and environmental factors. Twin studies in SLE have shown varying levels of concordance. This study…
Abstract Number: 1716 • ACR Convergence 2024
Comparing the Risk of Severe Infections Associated with Different Classes of Biologic or Targeted Synthetic Agents for Inflammatory Arthritis: A Population-based Study
Kasra Moolooghy¹, Hui Xie², Yufei Zheng³, J. Antonio Avina-Zubieta¹ and Diane Lacaille¹, ¹Arthritis Research Canada, University of British Columbia, Vancouver, BC, Canada, ²Arthritis Research Canada, Simon Fraser University, Vancouver, BC, Canada, ³Arthritis Research Canada, Vancouver, BC, Canada
Background/Purpose: Various classes of biologic and targeted synthetic DMARDs (b/tsDMARDs) are now available for treatment of inflammatory arthritis (IA), but little information on their relative…
Abstract Number: 1953 • ACR Convergence 2023
Mortality Trends in Polymyositis and Dermatomyositis in Mexico: A General Population-based Study from 2000 to 2019
CLAUDIA MENDOZA PINTO¹, Pamela Munguía-Realpozo¹, Ivet Etchegaray-Morales², Mario García-Carrasco², Paulina Cortés-Hernández¹, Roberto Arreguín-Reyes¹, Jorge Ayón-Aguilar¹ and Gabriel Rodríguez-Castillo², ¹Instituto Mexicano del Seguro Socia, Puebla, Mexico, ²Medicine School, Benemérita Universidad Autónoma de Puebla, Puebla, Mexico
Background/Purpose: Patients with polymyositis and dermatomyositis (PM/DM) present multiple complications that may lead to increased mortality rates and data on PM/DM mortality in Mexico is…
Abstract Number: 2406 • ACR Convergence 2023
Risk of Large Vessel Complications in Patients with Giant Cell Arteritis, a Population-based Study
Mohanad Elfishawi¹, Mahmut Kaymakci¹, Sara Achenbach², Cynthia Crowson¹, Tanaz Kermani³, Cornelia M. Weyand⁴, Matthew Koster¹ and Kenneth Warrington¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Rochester, MN, Rochester, MN, ³University of California Los Angeles, Los Angeles, CA, ⁴Mayo Clinic School of Medicine and Stanford University, Rochester, MN
Background/Purpose: Large vessel (LV) complications are known to occur in patients with giant cell arteritis (GCA). The magnitude of risk compared to the general population…
Abstract Number: 0108 • ACR Convergence 2023
Decoding Antiphospholipid Syndrome Laboratory Test Outcomes in a Large Multicenter Electronic Health Record Database
Emily Balczewski, Wenying Liang, Amala Ambati, Yu Zuo, Karandeep Singh and Jason Knight, University of Michigan, Ann Arbor, MI
Background/Purpose: Electronic health record (EHR) data provide an inexpensive, information-rich tool to study rare diseases like antiphospholipid syndrome (APS). Many such studies rely on structured…
Abstract Number: 2468 • ACR Convergence 2023
Association Between Gut Microbiome-related Metabolites and Symptomatic Hand Osteoarthritis in Two Independent Cohorts
Jie Wei¹, Zidan Yang², Jiatian Li³, Yuqing Zhang⁴, Weiya Zhang⁵, Michael Doherty⁵, Tuo Yang⁶, Yuanheng Yang³, Hui Li³, Yilun Wang³, Ziying Wu³, Changjun Li⁷, Guanghua Lei³ and Chao Zeng³, ¹Health Management Center, Xiangya Hospital Central South University, Changsha, China, ²Key Laboratory of Aging-related Bone and Joint Diseases Prevention and Treatment, Ministry of Education, Xiangya Hospital, Central South University, Changsha, China, ³Department of Orthopaedics, Xiangya Hospital, Central South University, Changsha, China, ⁴Division of Rheumatology, Allergy, and Immunology, Department of Medicine, Massachusetts General Hospital, Boston, MA, ⁵Academic Rheumatology, Clinical Sciences Building, University of Nottingham, City Hospital, Nottingham, United Kingdom, ⁶Department of Health Management Center, Xiangya Hospital, Central South University, Changsha, China, ⁷National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, China
Background/Purpose: Since gut microbiome dysbiosis can cause inflammatory disorders by affecting host metabolism, we postulate that the gut microbiome and related metabolites could play a…
Abstract Number: 0123 • ACR Convergence 2023
Improving Interpretation of Work Outcomes in Patients with Inflammatory Rheumatic Musculoskeletal Disease: General Population Reference Curves for Work Ability and At-work Productivity
Dafne Capelusnik¹, Wouter Smeets², Casper Webers³, Sofia Ramiro⁴, Elena Nikiphorou⁵, Roel Braekers², Laura Boekel⁶, Gertjan Wolbink⁷ and Annelies Boonen⁸, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Data science institute, Hasselt University, Hasselt, Belgium, ³Maastricht University, Maastricht, Netherlands, ⁴Department of Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ⁵King's College London, London, United Kingdom, ⁶Amsterdam Rheumatology and Immunology Center, Location Reade, Department of Rheumatology, Amsterdam, Netherlands, ⁷Reade, Amsterdam, Netherlands, ⁸Care and Public Health Research Institute (Caphri), Maastricht University, Maastricht, Netherlands
Background/Purpose: Data on self-reported presenteeism (limitations or reduced work productivity at work) in persons with inflammatory rheumatic and musculoskeletal diseases (iRMD) are challenging to interpret…
Abstract Number: 2536 • ACR Convergence 2023
DMARD Adherence During the COVID-19 Pandemic and Association with Risk of COVID-19 Infection
Tanya Selvam, Kelli Peterman, Arezoo Haghshenas and Lucy Liu, Kaiser Permanente Northern California, Oakland, CA
Background/Purpose: The COVID-19 pandemic affected medication adherence in patients with autoimmune disease (AD) due to their fear of contracting COVID-19, financial hardship, and medication shortage.…
Abstract Number: 0124 • ACR Convergence 2023
Utility of the 2019 EULAR/ACR SLE Classification Criteria Score as Predictor for Mortality and Hospitalizations in a Population-Based Cohort: The Lupus Midwest Network
Gabriel Figueroa-Parra¹, Andrew Hanson², Alain Sanchez-Rodriguez³, Jose Meade-Aguilar¹, Cynthia Crowson³ and Ali Duarte-Garcia³, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Patients with SLE experience increased all-cause mortality and have a higher risk of hospitalization than the general population. Recently the classification criteria for SLE…
Abstract Number: 0140 • ACR Convergence 2023
Extent of Recording of 2019 EULAR/ACR Classification Criteria for Systemic Lupus Erythematosus in a UK Healthcare Database
Jessica Ellis¹, Anita McGrogan², Neil McHugh², Ben Mulhearn³, Eleanor Korendowych⁴, John Pauling⁵, Ian Bruce⁶, Jenny Humphreys⁷ and Sarah Skeoch¹, ¹University of Bath; Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ²University of Bath, Bath, United Kingdom, ³Royal United Hospital Bath | University of Bath, Bath, United Kingdom, ⁴Royal National Hospital for Rheumatic Diseases, Bath, United Kingdom, ⁵North Bristol NHS Trust, Bristol, United Kingdom, ⁶University of Manchester, Manchester, United Kingdom, ⁷University of Manchester, Stockport, United Kingdom
Background/Purpose: The 2019 EULAR/ACR Classification Criteria allow classification of patients with systemic lupus erythematosus (SLE) for research. They reflect updates in current understanding of SLE…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].